Birmingham’s Vaxin Inc. will hunt for licensing agreements for its seasonal flu vaccine and for potential investors during a tour of Asia this month. Vaxin CEO Kent Van Kampen said his team’s mission during its visit to South Korea, China and Taiwan is developing relationships in its attempt to penetrate more Asian markets. The biotech firm’s efforts to tap into rapidly expanding Far East markets mirrors the state’s attempts to find a foothold for future international trade. Vaxin is searching for more investors and clinical trial partners. >>> Discuss This Story
